Arsanis IPO

11/15/2017

IPO

$40,000,000

As of September 30, 2017, we had cash of $26.3 million. We currently estimate that we will use the net proceeds from this offering, together with our existing cash, as follows: approximately $34 million to fund the development of ASN100 for the prevention of S. aureus pneumonia in mechanically ventilated patients; approximately $7 million to fund the development of ASN100 for other indications; approximately $6 million to advance our current pipeline of preclinical candidates other than ASN500, which, in the near term, we plan to advance entirely with funding from the Bill & Melinda Gates Foundation, or the Gates Foundation, and to research and develop additional preclinical product candidates; and the remainder for working capital and other general corporate purposes. We currently estimate that, if we receive additional net proceeds of $18.6 million from the sale of shares of common stock to NEA in the proposed concurrent private placement, we will use such net proceeds as follows: ap

Publicly-held

Biopharmaceutical

890 Winter St. 230
Waltham, MA 02451
USA

Not Recorded

Arsanis (NASDAQ: ASNS) is a biosciences company developing infectious disease treatments based on bacterial protein and carbohydrate antigens.